AstraZeneca (AZN) is considering a shift in the production of some medicines from Europe to the U.S. in order to sidestep potential tariffs on imports introduced by the Trump administration, Pharmaphorum reports. CEO Pascal Soriot says the company, which already operates 11 manufacturing sites in the U.S., is planning “even greater” investment in the U.S. for making medicines destined for U.S. domestic use.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca: Strong Buy Rating Backed by Oncology Growth and Promising Pipeline
- AstraZeneca’s Strong EPS Performance and Strategic Developments Justify Buy Rating
- AstraZeneca Reports Strong Q1 2025 Growth
- AstraZeneca’s Earnings Call: Strong Growth Amid Challenges
- EsoBiotec to present preclinical proof-of-concept data for ENaBL-T